Skip to main content
Premium Trial:

Request an Annual Quote

Danaher Completes Acquisition of Cepheid

NEW YORK (GenomeWeb) ­– Danaher announced Friday that it has completed its $4 billion acquisition of Cepheid.

Cepheid has been merged into Copper Merger Sub, a wholly owned subsidiary of Danaher, resulting in Cepheid becoming an indirect wholly owned subsidiary of Danaher.

Each outstanding share of Cepheid common stock was cancelled — except for shares held by Danaher, Copper Merger Sub, Cepheid, and respective subsidiaries — and converted into $53.00 per share in cash.

Cepheid's common stock will no longer be traded on the Nasdaq.

Danaher's shares rose nearly 2 percent to $78.30 in morning trading on the New York Stock Exchange.

The Scan

Billions for Antivirals

The US is putting $3.2 billion toward a program to develop antivirals to treat COVID-19 in its early stages, the Wall Street Journal reports.

NFT of the Web

Tim Berners-Lee, who developed the World Wide Web, is auctioning its original source code as a non-fungible token, Reuters reports.

23andMe on the Nasdaq

23andMe's shares rose more than 20 percent following its merger with a special purpose acquisition company, as GenomeWeb has reported.

Science Papers Present GWAS of Brain Structure, System for Controlled Gene Transfer

In Science this week: genome-wide association study ties variants to white matter stricture in the brain, and more.